Analyst Price Targets — ABCL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2024 1:14 pm | Gary Nachman | BMO Capital | $5.00 | $2.74 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital |
| August 23, 2024 11:57 am | Scott Schoenhaus | KeyBanc | $5.00 | $2.60 | StreetInsider | KeyBanc Reiterates Overweight Rating on AbCellera Biologics (ABCL) |
| May 8, 2024 2:46 am | Scott Schoenhaus | KeyBanc | $7.00 | $3.84 | StreetInsider | AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc |
| January 6, 2023 9:07 am | — | Leerink Partners | $18.00 | $9.63 | Benzinga | SVB Leerink Maintains Outperform on AbCellera Biologics, Lowers Price Target to $18 |
| December 15, 2022 4:41 am | Andrea Tan | Goldman Sachs | $30.00 | $10.13 | TheFly | AbCellera initiated with a Buy at Goldman Sachs |
| November 16, 2022 7:11 am | — | Truist Financial | $29.00 | $14.49 | Benzinga | Truist Securities Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $29 |
| August 10, 2022 8:56 am | — | Credit Suisse | $34.00 | $11.85 | Benzinga | Credit Suisse Maintains Outperform on AbCellera Biologics, Lowers Price Target to $34 |
Latest News for ABCL
AbCellera Biologics shares jumped 9.3% after hours to $3.52 following an 83% earnings beat in Q4 2025.
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.11 per share a year ago.
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus recommendation of "Hold" from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ABCL.
U.S. House Trading
No House trades found for ABCL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.